Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

Timothy R Smith, Egilius L H Spierings, Roger Cady, Joe Hirman, Anders Ettrup, Vivienne Shen, Timothy R Smith, Egilius L H Spierings, Roger Cady, Joe Hirman, Anders Ettrup, Vivienne Shen

Abstract

Background: Patients with migraine have an increased relative risk of cardio- and cerebrovascular events, and some migraine treatments may exacerbate this risk. The primary objective of this analysis was to determine whether the rate of cardiovascular adverse events was higher for patients with migraine treated with the migraine-preventive eptinezumab, compared with patients receiving placebo.

Methods: Cardiovascular outcomes in patients with migraine were pooled across four clinical trials (phase 1b, phase 2, and two phase 3 trials) for use of eptinezumab as a preventive migraine treatment for up to 1 year. In all studies, treatment-emergent adverse events (TEAEs) that occurred after the first dose of study treatment (eptinezumab 100 mg, 300 mg, 1000 mg, or placebo) and vital signs were recorded through study completion.

Results: Cardiovascular TEAEs were rare across all four clinical trials, and rates were similar between patients receiving eptinezumab and those receiving placebo. Cardiovascular TEAEs that did occur were mild or moderate in severity; there were no serious adverse events as per FDA definition. Vital signs (systolic blood pressure, diastolic blood pressure, and heart rate) were not meaningfully different across treatment groups over the course of 56 weeks, compared to placebo. Treatment with eptinezumab did not result in significant new or changed cardiovascular medications used concomitantly compared to placebo.

Conclusions: In this post hoc analysis of four clinical trials for eptinezumab, doses of 100 mg, 300 mg, and 1000 mg (more than 3 times the highest approved dose) were not associated with clinically relevant changes in vital signs or significant changes in concomitant cardiovascular medication usage, and had low incidences of cardiovascular TEAEs, comparable to placebo.

Trial registration: NCT01772524 (Study 2), 01/21/2013; NCT02275117 (Study 5), 10/27/2014; NCT02559895 (PROMISE-1), 09/25/2017; NCT02974153 (PROMISE-2), 11/28/2016.

Keywords: CGRP; Cardiovascular; Eptinezumab; Migraine.

Conflict of interest statement

TRS has been a consultant and/or scientific advisor for Alder/Lundbeck, Amgen, Biohaven, Eli Lilly, Impel Neuropharma, and Theranica, and has received research support from Alder/Lundbeck, Allergan, Amgen, Biohaven, Charleston Labs, Eli Lilly, electroCore, Novartis, Novo Nordisk, Satsuma, Theranica, and Vorso.

ELHS received research grants as a clinical trial investigator from Alder BioPharmaceuticals and is also a member of Lundbeck’s Speaker Bureau.

RC, AE, and VS are employees of Lundbeck or one of its subsidiary companies.

JH is an employee of Pacific Northwest Statistical Consulting, Inc., a contracted service provider of biostatistical resources for H. Lundbeck A/S.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Mean Vital Sign Parameters Over Time: (A) Systolic Blood Pressure (BP), (B) Diastolic BP, and (C) Heart Rate

References

    1. GBD Headache collaborators (2018) global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2016;17(11):954–976. doi: 10.1016/s1474-4422(18)30322-3.
    1. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner TJ, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210. doi: 10.1111/j.1468-2982.2007.01288.x.
    1. Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, Mohsen A, Abuzaid A, Mansoor H, Mojadidi MK, Elgendy IY. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018;8(3):e020498. doi: 10.1136/bmjopen-2017-020498.
    1. Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR. Migraine and the risk of stroke, TIA, or death in the UK (CME) Headache. 2007;47(10):1374–1384. doi: 10.1111/j.1526-4610.2007.00937.x.
    1. Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR. Migraine incidence, comorbidity and health resource utilization in the UK. Cephalalgia. 2008;28(1):57–64. doi: 10.1111/j.1468-2982.2007.01469.x.
    1. Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, Willett WC, Manson JAE, Rexrode KM. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610. doi: 10.1136/bmj.i2610.
    1. Kurth T, Rist PM, Ridker PM, Kotler G, Bubes V, Buring JE. Association of migraine with aura and other risk factors with incident cardiovascular disease in women. JAMA. 2020;323(22):2281–2289. doi: 10.1001/jama.2020.7172.
    1. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–582. doi: 10.1038/nrneurol.2010.127.
    1. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350. doi: 10.1038/s41582-018-0003-1.
    1. Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ. Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol. 1986;87(4):533–536. doi: 10.1111/1523-1747.ep12455620.
    1. AIMOVIG . package insert. Thousand Oaks: Amgen Inc.; 2020.
    1. NURTEC ODT . package insert. New Haven: Biohaven Pharmaceuticals, Inc.; 2021.
    1. UBRELVY . package insert. Madison: Allergan USA, Inc.; 2021.
    1. QULIPTA . package insert. Dublin: Ireland AbbVie; 2021.
    1. Homma S, Kimura T, Sakai S, K-i Y, Miyauchi Y, Aonuma K, et al. Calcitonin gene-related peptide protects the myocardium from ischemia induced by endothelin-1: Intravital microscopic observation and 31P-MR spectroscopic studies. Life Sci. 2014;118(2):248–254. doi: 10.1016/j.lfs.2014.02.024.
    1. Mulder IA, Li M, de Vries T, Qin T, Yanagisawa T, Sugimoto K, et al. Anti-migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88(4):771–784. doi: 10.1002/ana.25831.
    1. Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjö M. Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005;45(5):476–484. doi: 10.1097/01.fjc.0000159639.59770.36.
    1. Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39(11):1455–1464. doi: 10.1177/0333102419854082.
    1. Oakes TM, Kovacs R, Rosen N, Doty E, Kemmer P, Aurora SK, Camporeale A. Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache. 2020;60(1):110–123. doi: 10.1111/head.13684.
    1. Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R. Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials. Headache. 2019;59(6):880–890. doi: 10.1111/head.13534.
    1. Garcia-Martinez LF, Raport CJ, Ojala EW, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, Karasek C, Allison D, Latham JA. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. JPET. 2020;374(1):93–103. doi: 10.1124/jpet.119.264671.
    1. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, ALD403 study investigators Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–1107. doi: 10.1016/s1474-4422(14)70209-1.
    1. Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075–1085. doi: 10.1177/0333102419858355.
    1. Ashina M, Saper J, Cady R, Schaeffler B, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1) Cephalalgia. 2020;40(3):241–254. doi: 10.1177/0333102420905132.
    1. Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology. 2020;94(13):e1365–e1377. doi: 10.1212/WNL.0000000000009169.
    1. Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache. 2020;60(10):2220–2231. doi: 10.1111/head.14007.
    1. Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021;21(1):126. doi: 10.1186/s12883-021-02123-w.
    1. Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021;22(1):16. doi: 10.1186/s10194-021-01227-5.
    1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW, On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–e743. doi: 10.1161/cir.0000000000000950.
    1. Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18(1):96. doi: 10.1186/s10194-017-0807-1.
    1. Ashina M, McAllister P, Cady R, Hirman J, Ettrup A. Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: post hoc analysis PROMISE-1 and PROMISE-2. Headache. 2021;61(S1):123.
    1. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J, The Triptan Cardiovascular Safety Expert Panel Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–425. doi: 10.1111/j.1526-4610.2004.04078.x.
    1. de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, Van Bortel LM. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther. 2000;68(4):418–426. doi: 10.1067/mcp.2000.110502.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj